Chimeric antigen receptor-T (CAR-T) cell therapy has been facing a challenging time with the recent the US Food And Drug Administration probe into the safety of certain types of CAR-Ts, which in the case of Swiss firm CRISPR Therapeutics AG have led it to review its development pipeline.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?